Drug Profile
Research programme: cancer therapeutics - Janssen Biotech/Weill Cornell Medicine
Latest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Weill Cornell Medical College
- Developer Janssen Biotech; Weill Cornell Medical College
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for research development in Prostate-cancer in USA
- 05 Jan 2017 Janssen Biotech and Weill Cornell Medicine enter into an option agreement to co-develop therapeutics for Cancer
- 05 Jan 2017 Early research in Prostate cancer in USA (unspecified route)